{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:04:10Z","timestamp":1788930250210,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"REUNI"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.bbr.2014.08.014","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T00:01:08Z","timestamp":1407888068000},"page":"390-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine"],"prefix":"10.1016","volume":"274","author":[{"given":"Jana\u00edna K.","family":"Barbiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronise M.","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele Suzete","family":"Persike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"da Silva Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"da Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suelen","family":"Lucio Boschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo M.S.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.B.F.","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2014.08.014_bib0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","article-title":"Parkinson disease: from pathology to molecular disease mechanisms","volume":"62","author":"Dexter","year":"2013","journal-title":"Free Rad Biol Med"},{"key":"10.1016\/j.bbr.2014.08.014_bib0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11533740-000000000-00000","article-title":"Gene therapy in Parkinson's disease: rationale and current status","volume":"24","author":"Feng","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2014.08.014_bib0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/187152712800792820","article-title":"New agents promote neuroprotection in Parkinson's disease models","volume":"11","author":"Santos","year":"2012","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.bbr.2014.08.014_bib0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2014.08.014_bib0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0035","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.20834","article-title":"The Parkinson's complex: parkinsonism is just the tip of the iceberg","volume":"59","author":"Langston","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tins.2013.06.003","article-title":"Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems","volume":"36","author":"Brichta","year":"2013","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bbr.2014.08.014_bib0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","article-title":"Depression in Parkinson disease: epidemiology, mechanisms and management","volume":"8","author":"Aarsland","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12264-010-0302-z","article-title":"Treatment strategies for Parkinson's disease","volume":"26","author":"Yuan","year":"2010","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.bbr.2014.08.014_bib0055","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neures.2011.08.008","article-title":"Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of \u03b1-lipoic acid against rotenone-induced parkinsonism and l-DOPA toxicity","volume":"71","author":"Abdin","year":"2011","journal-title":"Neurosci Res"},{"key":"10.1016\/j.bbr.2014.08.014_bib0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/CIA.S4145","article-title":"The role of rasagiline in the treatment of Parkinson's disease","volume":"5","author":"Leegwater-Kim","year":"2010","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.bbr.2014.08.014_bib0065","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2014.08.014_bib0070","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2337\/diab.43.2.204","article-title":"Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys","volume":"43","author":"Kemnitz","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.bbr.2014.08.014_bib0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/15209150050194297","article-title":"Thiazolidinediones: a comparative review of approved uses","volume":"2","author":"Sood","year":"2000","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.bbr.2014.08.014_bib0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-2094-8-91","article-title":"The PPAR-\u03b3 agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys","volume":"8","author":"Swanson","year":"2001","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.bbr.2014.08.014_bib0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0014-5793(92)80734-X","article-title":"Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver","volume":"309","author":"Gebel","year":"1992","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bbr.2014.08.014_bib0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/meta.2001.19415","article-title":"The ligands\/activators for peroxisome proliferator-activated receptor-\u03b1(PPA\u03b1) and PPAR-\u03b3 increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells","volume":"50","author":"Inoue","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.bbr.2014.08.014_bib0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/jcbfm.2009.185","article-title":"Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice","volume":"30","author":"Guo","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2014.08.014_bib0100","first-page":"441","article-title":"NF-\u03baB activity as a therapeutic target in chronic inflammation: recent advances","volume":"6","author":"Makarov","year":"2000","journal-title":"Mol Med"},{"key":"10.1016\/j.bbr.2014.08.014_bib0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1172\/JCI11916","article-title":"NF-\u03baB in neuronal plasticity and neurodegenerative disorders","volume":"107","author":"Mattson","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbr.2014.08.014_bib0110","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1073\/pnas.94.14.7531","article-title":"Nuclear translocation of NF-(B is increased in dopaminergic neurons of patients with Parkinson's disease","volume":"94","author":"Hunot","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbr.2014.08.014_bib0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neulet.2006.12.003","article-title":"p53 protein, interferon-\u03b3, and NF-\u03baB levels are elevated in the parkinsonian brain","volume":"414","author":"Mogi","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2014.08.014_bib0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0006-2952(01)00680-3","article-title":"6-Hydroxydopamine-induced nuclear factor-kappaB activation in PC12 cells","volume":"62","author":"Blum","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0125","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1471-4159.2002.01224.x","article-title":"Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells","volume":"83","author":"Wang","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.08.014_bib0130","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/jnen\/62.11.1144","article-title":"MPP+ induces the endoplasmic reticulum stress response in rabbit brain involving activation of the ATF-6 and NF-\u03baB signaling pathways","volume":"61","author":"Ghribi","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1 (Suppl.)","key":"10.1016\/j.bbr.2014.08.014_bib0135","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1017\/S0317167100046345","article-title":"The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man","volume":"11","author":"Burns","year":"1984","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.bbr.2014.08.014_bib0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainresbull.2012.04.011","article-title":"Cognitive deficits in animal models of basal ganglia disorders","volume":"92","author":"Brooks","year":"2013","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.bbr.2014.08.014_bib0145","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"2005"},{"key":"10.1016\/j.bbr.2014.08.014_bib0150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","article-title":"Behavioral despair in rats, a new model sensitive to antidepressant treatments","volume":"47","author":"Porsolt","year":"1978","journal-title":"Eur J Phamacol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0155","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1054\/bjoc.2001.1700","article-title":"Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia","volume":"84","author":"Beliz\u00e1rio","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbr.2014.08.014_bib0160","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1073\/pnas.040556597","article-title":"Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease","volume":"97","author":"Hartmann","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbr.2014.08.014_bib0165","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/433692a","article-title":"Cell biology: divide and conquer","volume":"433","author":"Hengartner","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2014.08.014_bib0170","doi-asserted-by":"crossref","unstructured":"Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson\u2018s disease: signals for neuronal degradation. Ann Neurol 2003;53(Suppl. 3):S61\u201370; discussion S70\u20132.","DOI":"10.1002\/ana.10489"},{"key":"10.1016\/j.bbr.2014.08.014_bib0175","first-page":"277","article-title":"Changes in cytokines and neurotrophins in Parkinson's disease","volume":"60","author":"Nagatsu","year":"2000","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.bbr.2014.08.014_bib0180","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1015131516649","article-title":"Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]","volume":"21","author":"Youdim","year":"2001","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0185","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.expneurol.2005.05.009","article-title":"Intra-nigral MPTP lesion in rats: behavioral and autoradiography studies","volume":"195","author":"Perry","year":"2005","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0190","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/FBP.0b013e32833a5c81","article-title":"Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease","volume":"21","author":"Kreisler","year":"2010","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0195","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbr.2010.07.033","article-title":"Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease","volume":"216","author":"Barbiero","year":"2001","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.08.014_bib0200","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.phrs.2012.02.008","article-title":"Differential susceptibility to the PPAR-\u03b3 agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease","volume":"65","author":"Laloux","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bbr.2014.08.014_bib0210","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.pnpbp.2008.05.020","article-title":"Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice","volume":"32","author":"Rosa","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.08.014_bib0215","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/FBP.0b013e328331b9bf","article-title":"Antidepressant-like effects of rosiglitazone, a PPAR\u03b3 agonist, in the rat forced swim and mouse tail suspension tests","volume":"20","author":"Eissa Ahmed","year":"2009","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0220","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fneur.2013.00090","article-title":"Imaging of dopamine in PD and implications for motor and neuropsychiatric manifestations of PD","volume":"4","author":"De La Fuente-Fernandez","year":"2013","journal-title":"Front Neurol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0225","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1017\/S1461145710000775","article-title":"The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures","volume":"13","author":"Millan","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0230","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1460-9568.2004.03586.x","article-title":"Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates","volume":"20","author":"Decamp","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bbr.2014.08.014_bib0235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.brainres.2009.01.028","article-title":"Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model","volume":"1262","author":"Decamp","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2014.08.014_bib0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0166-4328(01)00211-X","article-title":"Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia","volume":"124","author":"Da Cunha","year":"2001","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.08.014_bib0245","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbr.2008.10.010","article-title":"Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease","volume":"197","author":"Kumar","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.08.014_bib0250","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.0704908104","article-title":"Selective inhibition of NF-\u03baB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease","volume":"104","author":"Ghosh","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbr.2014.08.014_bib0255","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1471-4159.2003.02210.x","article-title":"Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I\u03baB\u03b1 induction and block of NF\u03baB and iNOS activation","volume":"88","author":"Dehmer","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.08.014_bib0260","doi-asserted-by":"crossref","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor \u03b1 negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-\u03baB and AP-1","volume":"274","author":"Delerive","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bbr.2014.08.014_bib0265","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1074\/jbc.M610153200","article-title":"Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor \u03b3: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and AKT pathway","volume":"282","author":"Kapoor","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bbr.2014.08.014_bib0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2007.09.029","article-title":"Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-\u03baB and JNK activation and suppression of COX-2 activity","volume":"192","author":"Xing","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0275","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2014.08.014_bib0280","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00018-011-0850-z","article-title":"Transgenic expression and activation of PGC-1a protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease","volume":"69","author":"Mud\u00f2","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bbr.2014.08.014_bib0285","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","article-title":"A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"80","author":"Burns","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbr.2014.08.014_bib0290","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mds.1037","article-title":"Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice","volume":"16","author":"Turmel","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2014.08.014_bib0295","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(96)12323-5","article-title":"Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,3,6-tetrahydropyridine (MPTP) treatment of mice","volume":"204","author":"Hassouna","year":"1996","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2014.08.014_bib0300","first-page":"649","article-title":"TUNEL-positive cells in the substantia nigra of C57BL\/6 mice after a single bolus of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"85","author":"Spooren","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2014.08.014_bib0305","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2990.2010.01107.x","article-title":"Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system","volume":"36","author":"Yu","year":"2010","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0310","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/35037739","article-title":"Apoptosis in the nervous system","volume":"407","author":"Yuan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2014.08.014_bib0315","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/35040009","article-title":"Apoptosis in neurodegenerative disorders","volume":"1","author":"Mattson","year":"2000","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0320","doi-asserted-by":"crossref","first-page":"e62905","DOI":"10.1371\/journal.pone.0062905","article-title":"Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbr.2014.08.014_bib0325","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.pharmthera.2005.08.007","article-title":"Peroxisome proliferator-activated receptors and inflammation","volume":"110","author":"Moraes","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bbr.2014.08.014_bib0330","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nri2748","article-title":"Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells","volume":"10","author":"Glass","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0335","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1189\/jlb.0803402","article-title":"Anti-inflammatory and antiproliferative actions of PPAR-\u03b3 agonists on T lymphocytes derived from MS patients","volume":"75","author":"Schmidt","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0340","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1096\/fj.05-5007com","article-title":"Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats","volume":"20","author":"Zhao","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.bbr.2014.08.014_bib0345","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3109\/s10165-009-0261-2","article-title":"A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis","volume":"20","author":"Goto","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0350","first-page":"323","article-title":"Inhibition of NF-\u03baB signaling by fenofibrate, a peroxisome proliferator-activated receptor-\u03b1 ligand, presents a therapeutic strategy for rheumatoid arthritis","volume":"23","author":"Okamoto","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.bbr.2014.08.014_bib0355","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuroscience.2011.07.046","article-title":"Rosiglitazone decreases peroxisome proliferator receptor-\u03b1 levels in microglia and inhibits TNF-\u03b1 production: new evidences on neuroprotection in a progressive Parkinson's disease model","volume":"194","author":"Carta","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2014.08.014_bib0360","first-page":"689181","article-title":"Do PPAR-gamma agonists have a future in Parkinson's disease therapy?","volume":"2011","author":"Carta","year":"2011","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.bbr.2014.08.014_bib0365","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-8587(13)70125-6","article-title":"Diabetes drugs and neurological disorders: new views and therapeutic possibilities","volume":"2","author":"Cesare Patrone","year":"2014","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432814005269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432814005269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T02:09:50Z","timestamp":1572660590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432814005269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":72,"alternative-id":["S0166432814005269"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2014.08.014","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2014.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}